For over three decades, a mainstay and goal of clinical oncology has been the development
of therapies promoting the effective elimination of cancer cells by apoptosis. This …

It has been proposed that a chronic state of inflammation correlated with aging known as
inflammaging, is implicated in multiple disease states commonly observed in the elderly …

Purpose: Although KRAS represents the most commonly mutated oncogene, it has long
been considered an “undruggable” target. Novel covalent inhibitors selective for the …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …

Rapid advances in the molecular characterization of tumors, including complete gene
sequencing of multiple cancers in the Cancer Genome Project, have led to an increased …

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR)
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …

Among the most extensively researched processes in the development and treatment of
cancer is inflammatory condition. Although acute inflammation is essential for the wound …

Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

Radio-and chemotherapy are the most common cancer treatment modalities. They cause
acute and late side effects on normal tissues, which is a burden for delivery of a high dose of …

Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib …